Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5369 - RalB GTPase: A potential novel target for RAS mutant colorectal cancer.


11 Sep 2017


Poster display session


Translational Research;  Colon and Rectal Cancer


Hajrah Khawaja


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


H. Khawaja, P. O'Reilly, D. McArt, T. Harrison, P. Johnston, S. Van Schaeybroeck

Author affiliations

  • Centre For Cancer Research And Cell Biology, Queen's University Belfast, BT9 7AE - Belfast/GB


Abstract 5369


Colorectal cancer is the 3rd most common cancer in the UK, with around 40,000 new cases diagnosed annually. CRC patients have a 5-year overall survival rate of 50% cases) are associated with poor prognosis; this mutation has proven to be an important predictive factor for response to EGFR targeted therapies. Failure to target the RAS oncogene has resulted in a concentrated effort to discover targets within the downstream components of this pathway. In this study, we evaluate the roles of the small GTPases, RalA and RalB, as novel targets in RAS mutant (MT) CRC. The RALGDS/RAL pathway constitutes a RAS effector pathway and mediates cell survival, proliferation and tumorigenesis. RalB in particular contributes to cell survival through TBK1 signalling.


We used an siRNA-based approach silencing RALA and RALB both individually and simultaneously in a panel of KRASMT and WT cells with and without the addition of the MEKi AZD6244 (Selumetinib). Knockdown efficiency and subsequent signalling events were assessed by western blotting. Flow cytometry and MTT assays were used to measure cell death and cell viability respectively. Connectivity mapping using data from microarray experiments was used to identify drugs mimicking the phenotype observed with siRALB, subsequently leading to the investigation of a TBK1 inhibitor which is currently ongoing.


We found that silencing RALB but not RALA, led to the greatest amount of cell death in RASMT but not WT CRC cells. In addition, a significant increase in cell death was observed when RALB silencing was combined with MEK inhibition. Cell death was found to be mediated by Caspase 8 and involved an upregulation of death receptor 5 (DR5). Furthermore, TBK1 inhibition was found to mimic the phenotype observed with siRALB.


RalB but not RalA, is associated with cell survival and may contribute to drug resistance in RASMT CRC. Thus, the development of novel RalB-specific therapies may lead to new treatment strategies for RAS MT CRC.

Clinical trial identification

Legal entity responsible for the study

Queen's University Belfast


Queen's University Belfast, Cancer Research UK


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.